secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001213900-23-016445
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals receives Nasdaq extension to Aug 28, 2023 to regain $1.00 bid price compliance
--------------------------------------------------------------------------------

- Nasdaq granted 180-day extension until August 28, 2023 to meet minimum $1.00 closing bid price.
- Company failed to regain compliance by original deadline of February 27, 2023.
- Compliance can be achieved if stock closes at $1.00+ for 10 consecutive business days before deadline.
- If not compliant by Aug 28, 2023, Nasdaq will delist; company may appeal.
- Company considering reverse stock split among options to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023016445/0001213900-23-016445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023016445/ea174538-8k_adialpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-016445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer